New Stability Indicating Method for the Simultaneous Determination of Impurities Present in Candesartan Cilexetil and Hydrochlorothiazide Tablets by Ultra Performance Liquid Chromatography with Photo Diode Array Detector
More details
Hide details
APL Research Centre, INDIA
GITAM University, INDIA
M. V. V. N. Murali Krishna   

APL Research Centre (A Division of Aurobindo Pharma Limited), Survey No. 313, Bachupally, Quthubullapur Mandal, Ranga reddy District, Hyderabad-500072, Telangana, India
Online publication date: 2016-12-13
Publication date: 2016-12-13
Eurasian J Anal Chem 2017;12(2):127–149
A simple, rapid Reverse phase – Ultra Performance liquid chromatography (RP-UPLC) method was developed and validated for the simultaneous determination of thirteen known potential impurities present in Candesartan cilexetil and Hydrochlorothiazide fixed dose combination drug product. Chromatographic separation attained using 0.1% Perchloric acid in water and acetonitrile as Mobile phase-A and B respectively. The components were efficiently separated in Acquity UPLC HSS T3, 100 mm x 2.1 mm with 1.8 μm particle size column. Flow gradient elution mode with initial flow rate of 0.5 mL.min-1 followed by 0.6 mL.min-1 was used. The impurities were quantified at a working wavelength of 220 nm. The developed method was validated as per International Conference on Harmonization (ICH) recommendations for specificity, linearity, precision, ruggedness, accuracy, sensitivity (Limit of Detection & Limit of Quantitation) and robustness. The present stability indicating method is having shorter run time which is helpful for fast analysis of samples during quality control testing with reduced solvent consumption in a cost and time effective approach.
Fogari, R., Mugellini, A., Derosa, G., & CANDIA (candesartan and diuretic vs. amlodipine in hypertensive patients) study group. (2011). Efficacy and Tolerability of Candesartan cilexetil/hydrochlorothiazide and Amlodipine in patients with poorly controlled mild-to-moderate essential Hypertension. International Journal of Clinical Medicine, 2, 64-68.
Heran, B. S., Wong, M. M. Y., Heran, I. K., & Wright, J. M. (2008). Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database of Systematic Reviews, 4, Art. No. CD003822.
Asif, H., Sabir A., Moloy M., & Parminder S. B. (2011). A Review on Candesartan, Pharmacological and Pharmaceutical Profile. Journal of Applied Pharmaceutical Science, 1(10), 12-17.
Antonio, S., & Lorenzo, G. (2006). Thiazide Diuretics in the Treatment of Hypertension, An Update. Journal of American Society of Nephrology, 17(4), supplement 2, S25-S29.
Melian, E. B., & Jarvis, B. (2002). Candesartan cilexetil plus hydrochlorothiazide combination, a review of its use in hypertension. Drugs, 62(5), 787-816.
Mancia, G., Omboni, S., & CARDIO. (Candesartan combined with diuretic in hypertension) study group. (2004). Candesartan plus hydrochlorothiazide fixed combination vs previous monotherapy plus diuretic in poorly controlled essential hypertensive patients. Blood Pressure supplement, 2, 11-17.
Spratt, J, C. S., Webb, D. J., Shiels, A., & Williams, B. (2001). Effects of candesartan on cardiac and arterial structure and function in hypertensive subjects. Journal of the Renin Angiotensin Aldosterone System, 2, 227–32.
Campbell, M., Sonkodi, S., Soucek, M., & Wiecek, A. (2001). A candesartan cilexetil/hydrochlorothiazide combination tablet provides effective blood pressure control in hypertensive patients inadequately controlled on monotherapy. Clinical and Experimental Hypertension, 23(4), 345-355.
Basawaraj, P., Raghavedra, R. N. G, Suvarna, J., Upendra, K., & Mahesh, G. M. (2011). Estimation of Candesartan cilextil in bulk and tablet dosage forms by U.V Spectrophotometric method. International Journal of Research in Ayurveda & Pharmacy, 2(1), 204-206.
Srinivas, G., Kumar, K. K., Kanumula, G. V., Priya V. M., & Mukkanti, K. (2012). A Stability Indicating UPLC Method for Candesartan in Bulk Drug Samples. American Journal of Analytical Chemistry, 3, 704-709.
Peepliwal, A. K., Bonde, C. G., & Mohanraj, K. (2010). Bioanalytical method development and its validation for determination of candesartan cilexetil by high performance liquid chromatography with UV Detection. Acta Pharm Sciencia, 52, 247–53.
Mohan, A., Shanmugavel, S., Goyal, A., Venkataraman, B. R., & Saravanan, D. (2009). Identification, isolation and characterization of five potential degradation impurities in candesartan cilexetil tablets. Chromatographia, 69, 403–603.
Zhang, Y. D., Wei, X. H., Wang, A. F., Xu, Y. J., Zhu, X. H., & Luo, J. M. (2004). HPLC Determination of Candesartan Cilexetil and its Related Substances. Central South Pharmacy, 2(2), 80-83.
Kumar, N. D. A., Sudhakar, B. K., Gosada, U., & Sharma, N. (2012). A validated ultra high-pressure liquid chromatography method for separation of candesartan cilexetil impurities and its degradents in drug product. Pharmaceutical Methods, 3(1), 31–39.
Bhagwate, S., & Gaikwad, N. J. (2013). Stability Indicating HPLC Method for the Determination of Hydrochlorothiazide in Pharmaceutical Dosage form. Journal of Applied Pharmaceutical Science, 3(2), 88-92.
Veeranjaneyulu, D., Aneesha, A., & Nandakishore, A. (2013). Stability indicating RP-HPLC method for the simultaneous determination of candesartan cilexetil and hydrochlorothiazide in bulk and dosage forms. Indian journal of research in pharmacy and biotechnology issn, 2321-5674(print) issn, 2320 – 3471(online).
Singh, B., Lokhandae, R. S., Dwivedi, A., Sharma, S., & Dubey, N. (2014). Improved simultaneous quantitation of candesartan and hydrochlorthiazide in human plasma by UPLC–MS/MS and its application in bioequivalence studies. Journal of Pharmaceutical Analysis, 4(2), 144–152.
Erk, N. (2003). Simultaneous Analysis of Candesartan Cilexetil and Hydrochlorothiazide in Human Plasma and Dosage Forms Using HPLC with a Photodiode Array Detector. Journal of Liquid Chromatography and Related Technologies, 26, 2581–91.
Balamuralikrishna, K., & Syamasundar, B. (2010). Development and validation of high performance liquid chromatographic method for the simultaneous estimation of candesartan cilexetil and hydrochlorothiazide in combined tablet dosage form. Der Pharma Chemica, 2, 231–7.
Annapurnaa, M. M., Narendra, A., & Kumar, K. R. (2012). Liquid Chromatographic Method for Determination of Candesartan Cilexetil and Hydrochlorothiazide in Pharmaceutical Dosage Forms. Journal of Drug Delivery & Therapeutics, 2(2), 48-54.
Mehta, B. H., & Morge, S. B. (2008). HPTLC-Densitometric Analysis of Candesartan Cilexetil and Hydrochlorothiazide in Tablets. Journal of Planar Chromatography, Modern TLC, 21(2), 173-176.
Devanaboyina, N., & Satyanarayana, T. (2012). Simultaneous Determination of Candesartan and Hydrochlorothiazide in Combined Pharmaceutical Dosage Form by New RP- HPLC Method. Research Journal of Pharmaceutical, Biological and Chemical Sciences, 3(1), 270-278.
Lakshmi Narasimham, Y. S., & Barhate Vasant, D. (2010). Development and validation of stability indicating UPLC method for the simultaneous determination of beta-blockers and diuretic drugs in pharmaceutical dosage forms. Journal of Chemical Metrology, 4(1), 1-20.
Eranki, R. J. V., Inti, G., Jayaraman, V., Vidiyala, S. R., & Sreeramulu, J. (2014). New stability indicating method for quantification of impurities in candesartan cilexetil and hydrochlorothiazide tablets by validated HPLC. International Journal for Pharmaceutical Research Scholars, 3(2), 100-112.
ICH. (2005). Validation of Analytical Procedures, Text and Methodology, Q2(R1).
ICH. (2005). Stability Testing of New Drug Substances and Products, Q1A(R2).
US FDA Guidance. (2000). Analytical Procedures and Methods Validation.
Official Methods of Analysis, 15th Ed. (1990). Association of Official Analytical Chemists International, Arlington, VA, XVII.
Validation of Compendial Methods <1225> (2012). The United States Pharmacopeia.
United States pharmacopeial Convention, 36th ed. (2012). The United States Pharmacopoeia, Rockville, MD.
Guideline for submitting samples and Analytical Data for Methods Validation, US Food and Drug Administration. (1987).